On July 2, Sanofi declined 3.01% in regular trading, trading at $41.375/share, with turnover of $117 million. The decline notably exceeded broader pharma sector losses, as Eli Lilly fell 1.71% and Merck dropped 1.70%.

The selloff was driven by continued fallout from the European Commission's formal antitrust investigation launched on June 26, which alleges Sanofi abused its dominant market position by conducting a misleading communication campaign disparaging CSL Seqirus' flu vaccine Fluad to boost sales of its own Efluelda vaccine. The regulator noted that Sanofi's claims contradicted assessments by the European Centre for Disease Prevention and Control and national immunization advisory groups in Germany and France. The EU had previously conducted dawn raids on Sanofi's German and French offices last September, and the formal probe escalation poses sustained reputational and operational risks.

Adding to the pressure, Sanofi disclosed in June that it discontinued a phase 3 trial of riliprubart for chronic inflammatory demyelinating polyneuropathy following an interim review, reinforcing investor concerns over pipeline setbacks. Analysts have flagged that the company's stock has declined approximately 13% over the past twelve months amid mixed clinical results and strategic uncertainty ahead of Dupixent's eventual patent expiration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)